AstraZeneca secures alternative supply of adrenaline for New Zealand
AstraZeneca has secured an approved source of adrenaline to meet the current shortage in New Zealand, General Manager
Lance Gravatt said today.
Mr Gravatt said AstraZeneca had been approached by PHARMAC and Medsafe to assist with the shortage, and it worked hard
to secure a supply for New Zealand at very short notice.
“Following the request we have been able to locate AstraZeneca brand adrenaline stock from Australia, and have been
able to retain this for the New Zealand market.
“This stock can be used in exactly the same way as the existing supplies of adrenaline in the New Zealand market and is
clearly labelled ‘adrenaline’.”
“This should avoid the potential confusion in emergency situations, which was a concern expressed by the New Zealand
Medical Association about other alternatives to the regular supply,” Mr Gravatt said.
He said the product was approved by Medsafe, and AstraZeneca was working with PHARMAC to finalise delivery.
ends